Valuation : Imunon, Inc.

Market Cap 8.98M 7.74M 7.29M 6.64M 12.48M 852M 12.55M 86.12M 33.52M 433M 33.71M 32.98M 1.44B P/E 2026 *
-0.67x
P/E 2027 * -0.86x
Enterprise Value 8.98M 7.74M 7.29M 6.64M 12.48M 852M 12.55M 86.12M 33.52M 433M 33.71M 32.98M 1.44B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.86%
Yield 2026 *
-
Yield 2027 * -
1 day-1.84%
1 week-3.61%
Current month-1.84%
1 month+0.63%
3 months-25.58%
6 months-50.77%
Current year-58.01%
1 week 1.55
Extreme 1.55
1.65
1 month 1.52
Extreme 1.52
1.72
Current year 1.47
Extreme 1.47
4.2
1 year 1.47
Extreme 1.47
6.02
3 years 1.47
Extreme 1.47
47.61
5 years 1.47
Extreme 1.47
219.13
10 years 1.47
Extreme 1.47
3,780.03
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

General Counsel

-2,449 0.0971%
8/14/26 Free

Chief Technology Officer

3,516 0.1395%
8/14/26 Free

Chief Executive Officer

6,615 0.2624%
Change 5-day change 1-year change 3-year change Capi.($)
-1.84%-3.61%-73.02%-89.95% 8.98M
-0.25%-4.10%+38.38%+92.61% 68.21B
+1.69%+0.29%+48.55%+89.56% 64.25B
-0.25%-1.92%-10.72%+436.70% 26.54B
+0.33%-10.61%+1.95%-16.27% 25.61B
+2.00%+1.11%+32.14%-18.02% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.65%-5.28%-1.12%+534.90% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
Average +0.00%-3.28%+33.73%+174.57% 26.31B
Weighted average by Cap. +0.33%-3.22%+41.88%+158.83%

Financials

2026 *2027 *
Net sales - -
Net income -14.47M -12.48M -11.74M -10.69M -20.11M -1.37B -20.22M -139M -54.01M -698M -54.32M -53.14M -2.32B -19.34M -16.69M -15.7M -14.3M -26.89M -1.84B -27.04M -186M -72.23M -934M -72.63M -71.05M -3.1B
Net Debt - -
Logo Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
20
Date Price Change Volume
26-09-01 US$1.600 -1.84% 33,859
26-08-31 US$1.630 +1.87% 18,399
26-08-28 US$1.600 0.00% 82,359
26-08-27 US$1.600 -1.84% 21,730
26-08-26 US$1.630 -1.81% 48,408
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.600USD
Average target price
17.00USD
Spread / Average Target
+962.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMNN Stock